Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02553798 · ClinicalTrials.gov registry record · Phase 3
Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis
A Phase 3 study, sponsored by Journey Medical Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 564
- Enrollment target
NCT02553798 is a Phase 3 study that has completed, run by Journey Medical Corporation. The registered enrollment target is 564 participants.
The verdict
NCT02553798, a Phase 3 study, has completed, sponsored by Journey Medical Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 564 participants
- Enrollment target
Study Summary
This is an open-label, long-term safety study of glycopyrronium topical wipes, enrolling up to 660 subjects with primary axillary hyperhidrosis who participated in either the DRM04-HH04 or DRM04-HH05 studies.
Interventions
- DRUG Glycopyrronium Topical Wipes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 564 participants |
| Start Date | 2015-08 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02553798
The ClinicalTrials.gov registry entry for NCT02553798 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 564 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Journey Medical Corporation, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Glycopyrronium Topical Wipes is the first listed.
NCT02553798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02553798 about?
NCT02553798 is a clinical study titled "Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis". This is an open-label, long-term safety study of glycopyrronium topical wipes, enrolling up to 660 subjects with primary axillary hyperhidrosis who participated in either the DRM04-HH04 or DRM04-HH05 studies.
What is the current status of trial NCT02553798?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 564 participants. The study started on 2015-08. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02553798?
The interventions under investigation include: Glycopyrronium Topical Wipes (DRUG).
Who is sponsoring clinical trial NCT02553798?
This trial is sponsored by Journey Medical Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.